Top Ten most popular articles on Pharmafile.com this week

pharmafile | July 14, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, life sciences, pharma, pharmaceutical, top ten 

As the week comes to a close, we bring you the stories that were most read by our readers – and what a week it’s been for the industry. The last seven days saw the World Health Organization (WHO) make an official statement on the emergence of what many are calling ‘super gonorrhoea’. In what could be a landmark ruling, an FDA panel voted unanimously in favour of recommending its first-ever CAR T therapy for the treatment of cancer. But Teva stole the headlines with the illicit dealings of an ex-excutive and her rival CEO boyfriend, as well as the shock news that AstraZeneca’s CEO Pascal Soriot will be jumping ship to the generics firm.

Check out the week’s ten most popular articles on Pharmafile.com now!

10. Gilead to launch injunction against Mylan and Actavis over HIV generics in Ireland

Gilead is expected to launch injunctive action against rivals Mylan and Actavis over the allegation that they are planning to offer a generic version of Gilead’s antiretroviral HIV drug Truvada.

9. Celgene plays catch up with $1.4 billion immunotherapy deal

Celgene’s deal with BeiGene is a licensing agreement for its PD-1 immunotherapy, BGB-A317; it is structured so that BeiGene receives $263 million upfront, a further $150 million equity stake and close to $1 billion locked into milestone agreements.

8. Shire and Roche haemophilia spat spills into court

Roche released new scientific data at a conference in Berlin regarding its developmental drug in haemophilia, emicizumab, and Shire chose the day prior to announce its injunction against the company, stoking a heated battle in the haemophilia sector.

7. Oral sex creating super-gonorrhoea

The WHO has announced that data from across 77 different countries show that the sexually-transmitted infection (STI) gonorrhoea is becoming increasingly antibiotic-resistant. 

6. Novartis’ breakthrough cancer treatment receives FDA advisory approval

In what could well be a game-changing decision for cancer treatment, the FDA advisory panel gave Novartis’ CAR-T Therapy, CTL019 (tisagenlecleucel), unanimous approval in a 10-0 vote in favour of the treatment.

5. Top 50 Selling Products in the World by 2022

Opdivo and Revlimid to compete for the top spot in 2022, while Humira is expected to step down following biosimilar launch.

4. European pharma pulls together to ensure ‘minimal disruption’ from Brexit

Pharmaceutical firms and patient groups have made it clear that they are united in the EMA’s relocation in order to ensure patient safety and health are not compromised.

3. Problematic facility inspection puts Biocon’s biosimilar EU approvals on hold

Biocon has been hit by regulator criticism which has forced its European biosimilar programme on hold following a March inspection which identified 35 deficiencies at the company’s production plant in Bengaluru, India. 

2. Teva accuses ex-employee of passing company secrets to boyfriend at rival generics firm

Teva has launched a lawsuit against Barinder Sandhu, its ex-Chief of Regulatory Affairs, who is accused of passing on trade secrets to her boyfriend Jeremy Desai, the CEO of a rival generics firm.

1. AstraZeneca’s CEO set for shock switch to Teva

Teva have swooped for Pascal Soriot, of AstraZeneca, to fill the vacancy in its CEO position in a move that has taken many by surprise.

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Zumutor’s cancer drug trial cleared by FDA

On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …

Latest content